Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02385214 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

MelmarT Melanoma Margins Trial Investigating 1cm v 2cm Wide Excision Margins for Primary Cutaneous Melanoma

Study acronym: MelMarT
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Phase: Phase 3 to Not applicable Site details revised at 2 of 20 sitesv10 Show 1 more changeShow less
    • Site details revised at 2 of 20 sites
  2. Primary completion date changed from estimate of Aug 5, 2026 to Aug 4, 2016v9
  3. 2 versions Re-verified since Oct 7, 2020, no change to tracked fieldsv7-v8
  4. Study sites: 15 to 20v6
  5. Primary and study completion dates: Dec 2029 to Aug 5, 2026 Start date: Dec 2014 to Jan 3, 2015v5 Show 1 more changeShow less
    • Start date: Dec 2014 to Jan 3, 2015
Show 3 earlier versionsHide 3 earlier versions
  1. Trial status: Recruiting to Active, Not Recruiting Site details revised at 15 of 15 sitesv4 Show 1 more changeShow less
    • Site details revised at 15 of 15 sites
  2. Re-verified, no change to tracked fieldsv3
  3. Study sites: 2 to 15v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the primary lesion for adult patients with a primary invasive cutaneous melanomas \>=1mm thick to determine differences in the rate of local recurrence and melanoma specific survival. A reduction in margins is expected to improve quality of life in patients
Trial Details
NCT Number NCT02385214
Lead Sponsor Melanoma and Skin Cancer Trials Limited
Collaborators: Peter MacCallum Cancer Centre, Australia, Norfolk and Norwich University Hospitals NHS Foundation Trust
Conditions Cutaneous Melanoma by AJCC V7 Stage
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov